CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced the
initiation of enrollment in an open-label Phase 1b clinical trial
designed to investigate the preliminary safety and activity of
aldoxorubicin plus ifosfamide/mesna as a first-line treatment in
subjects with various sarcomas.
for CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas investment picks